Status:
UNKNOWN
The Role of Natural Killer, Complement and T-lymphocytes in COVID-19 Disease, a Prospective Monocentric Study
Lead Sponsor:
Universitair Ziekenhuis Brussel
Conditions:
Complement Abnormality
Peripheral Blood Mononuclear Cells
Eligibility:
All Genders
Phase:
NA
Brief Summary
The current study is an open, non-randomized, monocentric, and interventional study. CoViD-19 patients will be recruited at UZ Brussel after informed consent is obtained. Whole blood and serum samples...
Eligibility Criteria
Inclusion
- Covid-19 patients
- Inclusion Criteria:
- Positive nasopharyngeal reverse transcriptase-polymerase chain reaction for SARS-Coronavirus-02
- Signed inform consent
- Healthy Volunteers
- Inclusion Criteria:
- Signed inform consent
Exclusion
Key Trial Info
Start Date :
September 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 1 2024
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT05258643
Start Date
September 1 2020
End Date
September 1 2024
Last Update
February 28 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
UZ Brussel
Jette, Brussels Capital, Belgium, 1090